Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Kevin Sheng-Po Yuan

Citation

Annals of Oncology (2019) 30 (suppl_9): ix20-ix21. 10.1093/annonc/mdz419

Authors

K.S. Yuan, C. Chang, S. Wu

Author affiliations

  • Director & Attending Physician, Department Of Radiation Oncology, Taipei Medical, Taipei Medical University - Municipal Wan Fang Hospital, 116 - Taipei/TW

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 55P

Background

To compare the toxicity profiles of contemporary stereotactic radiosurgery (SRS), fractionated radiotherapy (FRT) with modern techniques, or transsphenoidal surgery on nonfunctioning pituitary macroadenoma.

Methods

We enrolled patients with nonfunctioning pituitary macroadenoma and categorized them into three groups according to treatment modality to compare treatment outcomes: group 1, those receiving modern FRT; group 2, those receiving contemporary SRS; and group 3, that receiving transsphenoidal surgery.

Results

248 patients in total with nonfunctioning pituitary macroadenoma were selected in our study. In multivariable Cox proportional hazards regression analysis, adjusted HRs (aHRs; 95% confidence interval [CI]) of local recurrence were derived for the SRS and transsphenoidal surgery cohorts compared with the FRT cohort was no significant difference in secondary primary brain or head and neck cancers, hypopituitarism, and optic nerve injury between three treatment cohorts. In multivariable Cox proportional hazards regression analysis, adjusted HRs (aHRs; 95% confidence interval [CI]) of stroke risk were derived for the SRS and transsphenoidal surgery cohorts compared with the FRT cohort were 0.37 (0.14-0.99) and 0.51 (0.31-0.84), respectively.

Conclusions

Contemporary SRS and transsphenoidal surgery in treatment of nonfunctioning pituitary macroadenoma would bring in equal toxicity profiles. Modern FRT might increase risk of stroke in treatment of nonfunctioning pituitary macroadenoma significantly.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.